Answers are grounded in this paper and cite their sources.
Background Influenza viruses remain a formidable global health challenge, characterized by rapid genetic mutation, antigenic drift, and pandemic potential. Seasonal outbreaks impose substantial socioeconomic burdens, highlighting the urgent need for novel antiviral strategies beyond existing neuraminidase inhibitors, which are increasingly compromised by drug resistance and limited efficacy. While oseltamivir is a key treatment, the rise of drug-resistant variants highlights the urgent need for new therapeutic options. Methods This study first evaluated Xuebijing injection (XBJ) and its component herb S. miltiorrhiza for anti-influenza activity, followed by chemical profiling and compound prioritization. Salvianolic acid C was subsequently selected for detailed antiviral and mechanistic characterization, using qRT-PCR, Western blotting, plaque reduction assays, and immunofluorescence. Further, we evaluated its antiviral effects against other subtypes, including H3N2, H9N2, and influenza B virus. The therapeutic efficacy of salvianolic acid C was assessed in a murine model of lethal H1N1 infection by evaluating survival rates, lung viral loads, lung histopathology, and cytokine profiles. Administration and time-of-addition assays were conducted to determine the stage-specific inhibitory effects of salvianolic acid C in the viral life cycle. The interaction between salvianolic acid C and the NA protein was investigated using Bio-Layer Interferometry, cellular thermal shift assays, drug affinity responsive target stability assays, and neuraminidase inhibition assays. Results Xuebijing injection and Salvia miltiorrhiza Bunge exhibited clear anti-influenza activity. Salvianolic acid C displayed potent in vitro anti-influenza activity against multiple subtypes (H1N1, H3N2, H9N2) with favorable EC 50 and SI values, inhibiting viral NP/NA expression and progeny virus release. In vivo , salvianolic acid C improved the survival rate, reduced the lung index and viral load, and alleviated lung pathological damage in H1N1/PR8-infected mice. Mechanistically, salvianolic acid C acted at the stage of viral release without affecting viral RNA synthesis. BLI analysis showed that salvianolic acid C bound to NA with a KD of 1.49 μM, and it inhibited NA enzymatic activity. Conclusion SAC was identified as a promising anti-influenza compound that interacts with viral NA, inhibits NA enzymatic activity, and predominantly interferes with the late stage of the viral life cycle.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: